Etanercept Biosimilar - Shilpa Biologicals
Alternative Names: SBDM-002Latest Information Update: 23 Dec 2022
At a glance
- Originator Shilpa Biologicals
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 30 Nov 2022 Phase-I clinical trials in Ankylosing spondylitis in India (unspecified route) before November 2022 (Shilpa Biologicals pipeline, November 2022)
- 30 Nov 2022 Phase-I clinical trials in Juvenile rheumatoid arthritis in India (unspecified route) before November 2022 (Shilpa Biologicals pipeline, November 2022)
- 30 Nov 2022 Phase-I clinical trials in Plaque psoriasis in India (unspecified route) before November 2022 (Shilpa Biologicals pipeline, November 2022)